Omada Health’s Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

Core Insights - Omada Health's GLP-1 companion program significantly enhances medication persistence, leading to weight loss outcomes comparable to clinical trials [1][4][6] - Real-world data indicates that many patients struggle with medication adherence, with one-third discontinuing GLP-1 use within the first month [2][3] - The Enhanced GLP-1 Care Track program provides targeted support to help patients overcome barriers to medication persistence, resulting in higher adherence rates [5][6] Group 1: Program Effectiveness - Omada's analysis showed that members who adhered to their GLP-1 medication for 24 weeks achieved an average weight loss of 12.1%, compared to 7.4% for those who discontinued early, representing a 64% relative increase [4] - The program demonstrated a persistence rate of 94% at 12 weeks and 84% at 24 weeks, significantly higher than previous studies which reported persistence rates ranging from 33% to 80% [3][4] Group 2: Support Mechanisms - The Enhanced GLP-1 Care Track offers comprehensive support, including education on dose titration, management of side effects, nutrition guidance, and exercise support [5][6] - Omada Health emphasizes the importance of providing resources to help members navigate healthcare options, particularly for those considering discontinuation due to access issues [5][6] Group 3: Industry Context - The increasing access to GLP-1 medications presents both opportunities and responsibilities for healthcare providers to ensure cost-effective and sustainable health benefits [6] - Omada Health has over a decade of experience and 29 peer-reviewed publications that validate its approach to chronic disease management and behavior change [7][8]